Ampio Pharmaceuticals Inc  

(Public, NYSEMKT:AMPE)   Watch this stock  
Find more results for K. Giles
+0.005 (0.46%)
Jul 29 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 0.95 - 1.02
52 week 0.84 - 4.32
Open 0.99
Vol / Avg. 350,995.00/1.57M
Mkt cap 52.87M
P/E     -
Div/yield     -
EPS -0.61
Shares 52.02M
Beta 0.43
Inst. own 22%

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin - -2900.22%
Operating margin - -2864.80%
EBITD margin - -2767.05%
Return on average assets -75.09% -55.87%
Return on average equity -98.81% -62.09%
Employees 21 -
CDP Score - -


373 Inverness Pkwy Ste 200
ENGLEWOOD, CO 80112-5898
United States - Map
+1-720-4376500 (Phone)
+1-720-4376501 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Ampio Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused primarily on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. The Company's two lead product candidates in development are Ampion for osteoarthritis of the knee and Optina for diabetic macular edema. Ampion is a sub 5000 molecular weight fraction of commercial human serum albumin (HSA). Optina is a low-dose formulation of danazol. The Ampio segment consists of its biopharmaceuticals compounds and the clinical trials associated with them. The Company is primarily developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depleting available phosphate needed for the inflammation process, and decreasing vascular permeability.

Officers and directors

Michael Macaluso Chairman of the Board, Chief Executive Officer
Age: 63
Bio & Compensation  - Reuters
Gregory A. Gould CPA Chief Financial Officer, Treasurer, Corporate Secretary
Age: 49
Bio & Compensation  - Reuters
David Bar-Or M.D. Chief Scientific Officer, Director
Age: 66
Bio & Compensation  - Reuters
Vaughan Lennox Clift M.D. Chief Regulatory Affairs Officer
Age: 53
Bio & Compensation  - Reuters
Philip H. Coelho M.D. Independent Director
Age: 71
Bio & Compensation  - Reuters
Richard B. Giles Independent Director
Age: 65
Bio & Compensation  - Reuters
David R. Stevens Ph.D. Independent Director
Age: 65
Bio & Compensation  - Reuters